Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

Int J Mol Sci. 2015 Jul 30;16(8):17514-34. doi: 10.3390/ijms160817514.


Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could contribute to help clinical decisions move toward a precision medicine and a better clinical outcome for these patients. In this review, we describe the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL).

Keywords: molecular profiling; pharmacogenetics; plasma cell leukemia; precision medicine; risk stratification.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Humans
  • Leukemia, Plasma Cell / classification
  • Leukemia, Plasma Cell / drug therapy*
  • Leukemia, Plasma Cell / genetics*
  • Molecular Targeted Therapy
  • Neoplasm Proteins / genetics*
  • Pharmacogenetics*
  • Precision Medicine
  • Prognosis
  • Treatment Outcome


  • Antineoplastic Agents
  • Neoplasm Proteins